Josh Barer

Josh Barer has a diverse work experience, beginning in 2011 when they joined the Executive Advisory Board and became a Graduate Fellow at the Center on Religion, Culture, and Conflict at Drew University. In 2015, they became a Venture Advisor at Israel Biotech Fund. In 2016, they were appointed Managing Director at Sunflower Life Sciences. In 2017, they joined Barer & Son Capital as Managing Partner, and also became a Board Member for Trickle Up and a Board Observer for NexImmune, Inc. In 2018, they were appointed Director at AsclepiX Therapeutics. In 2019, they became Co-Founder of Hibiscus BioVentures, and also joined Family Promise, Inc. as a Board Member. In 2020, they became the Chief Executive Officer of Hibiscus Capital Management.

Josh Barer began their education at Rutgers University in 2006, where they earned a BA in Jewish Studies, Middle Eastern Literature and Languages in 2011. In 2008, they studied Middle Eastern Studies at the University of Haifa and also attended Credit Suisse YIO that same year. From 2011 to 2013, they attended Drew University and studied Peace and Conflict Studies.